- Topic
10k Popularity
14k Popularity
36k Popularity
24k Popularity
8k Popularity
6k Popularity
70k Popularity
141k Popularity
70k Popularity
1765k Popularity
- Pin
- #Gate Ranks Top 4 Exchange#
Gate has reached the Top 4 global crypto derivatives exchanges on CoinMarketCap, with a 24-hour trading volume exceeding $15 billion. Enjoy some of the lowest fees in the industry—maker fees as low as 0.015%. Gate is committed to providing users with a more efficient and cost-effective trading experience, making it your top choice for crypto trading!
Start trading now:
👉 Spot Trading: https://www.gate.com/trade
👉 Alpha Trading: https://www.gate.com/alpha
👉 Futures Trading: https://www.gate.com/futures
💬 What derivatives or other products have you recently traded
- 🎉 CandyDrop 5.0: 5 BTC Mega Airdrop is here!
🎁 Total Prize Pool: 5 BTC
📈 Trade any futures pair ≥ 50,000 USDT to earn Candy
👥 Invite friends to unlock more BTC rewards
🗓️ Event Time: June 27, 9:00 – July 11, 9:00 (UTC)
🎯 Max reward per user: 0.01 BTC
👉 Join Now >> https://www.gate.com/candy-drop/detail/BTC-59
⚡ 100% real airdrop — limited time only!
- Gate Alpha 2nd Points Carnival Round 4 Hot Launch! Trade to Share $30,000 MORE & Alpha Points
Trade $MORE to unlock Listing Airdrops + $300K Points Prize Pool!
💰 Total Airdrop Volume: $30,000 MORE, Limited slots—first come, first served!
✅ Total Points: 2 Alpha Points per trade—accumulate points to share the $300K prize pool!
🔥Trade the Hottest On-Chain Assets First
For more information: https://www.gate.com/campaigns/1342alpha?pid=X&c=MemeBox&ch=vxDB0fQ5
- 📢 $MORE is launching on Gate Alpha!
Users will be able to trade Moonveil ( $MORE ) directly via Gate Alpha — Gate's one-stop on-chain trading portal.
🔥Trade the Hottest On-Chain Assets First
https://www.gate.com/alpha
- 🎁 Gate Alpha Airdrop Alert!
To celebrate the listing of $EGL1 on Gate Alpha @GateioAlpha
A limited-time airdrop campaign is now live — with 149,254 EGL1 up for grabs!
First Come, First Served
🔥Trade the Hottest On-Chain Assets First
For more information: https://www.gate.com/campaigns/1355?pid=X&ch=0cykUS3i
Novo Nordisk: 7.2mg semaglutide phase 3 clinical trial met the primary endpoint with a weight loss of 20.7% at 72 weeks.
On January 18, Jins data reported that on January 17 local time, Novo Nordisk announced the main results of the 3b phase clinical trial STEP UP. In the STEP UP obesity trial, subcutaneous injection of 7.2mg semaglutide once a week resulted in a weight loss of 20.7% at 72 weeks, and a weight loss of 18.7% regardless of treatment compliance. The trial met its primary endpoint, with 7.2mg semaglutide showing statistically significant and superior weight loss compared to placebo at 72 weeks.